ClinicalTrials.gg
CompletedNCT06256562Updated Oct 1, 2025

A Study of GZR18 Injection in Obese/Overweight Patients

A Phase 2 interventional study of GZR18 and Placebo in Obesity and Overweight, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2023, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Enrollment
4th of 15
340 · median 140
Started
2023
with 1 other
Phase 2
2 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
5 of 15
Gan and Lee Pharmaceuticals, USA

Among the 15 studies testing bofanglutide in Obesity, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 2, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18-75 years (inclusive).

    1. Obese subjects (≥28 kg/m2), Or overweight subjects (24 kg/m2≤BMI\<28 kg/m2) with at least one comorbidity.
    2. Able to understand the procedures and methods in this study; willing and able to maintain a stable diet and exercise lifestyle during the research period, and willing to sign the ICF voluntarily.

Exclusion criteria

  1. Limb deformities or defects affecting height and body weight measurement.

    1. Pregnant or lactating women, men or women of unwilling to use throughout the study and for 6 months after the last dose of drug.
    2. History of drug abuse within 1 year before screening, or positive results in drug abuse screening during screening or before randomization.
    3. Alcohol abuse history within 6 months prior to screening.
    4. Subjects who are known or suspected to be allergic to GLP-1 drugs or .
    5. Subjects with an absolute weight change greater than 5.0% due to any reason within the 3 months prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
340 participants (actual)

Study arms

  • Experimental
    GZR18

    GZR18 injection s.c.

    Drug: GZR18

  • Placebo comparator
    Placebo

    Placebo injection s.c.

    Other: Placebo

Interventions

  • DrugGZR18

    Titrated to dose 1, dose 2, dose 3 or dose 4

  • OtherPlacebo

    Administered the same volume as GZR18

06

What researchers measure

Primary outcomes

  1. Percent (%) change from baseline in body weight at the end of the study (W30)

    Time frame: 30 weeks

Secondary outcomes

  1. Proportion of subjects who achieved (yes/no) body weight reduction ≥5%, 10%, 15%, 20% from baseline.

    Time frame: 30 weeks

  2. Weight, waist circumference, waist-to-hip ratio (waist circumference/hip circumference), and body mass index (BMI)

    Changes from baseline

    Time frame: 30 weeks

  3. Percentage (%) of weight

    Change from baseline at the last safety follow-up visit (W33) after discontinuation

    Time frame: 33 weeks

  4. Glucose metabolism indicators: glycated hemoglobin A1C (HbA1c), fasting plasma glucose (FPG), fasting insulin, insulin resistance index (HOMA-IR), and islet β cell function (HOMA-β)

    Changes from baseline

    Time frame: 30 weeks

  5. Cardiovascular disease risk factors: blood pressure (SBP and DBP), pulse, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides (TG)

    Changes from baseline

    Time frame: 30 weeks

  6. Patient-reported weight-related quality of life scores: IWQoL-Lite-CT and SF-36 scale

    Changes from baseline

    Time frame: 30 weeks

  7. Anti-drug antibodies (ADAs) for GZR18 and neutralizing antibodies (NAbs) following GZR18 Injection

    Changes from baseline

    Time frame: 33 weeks

  8. AUClast, AUC0-inf, Tmax, λz, t1/2, tlag, CL/F, Vz/F, AUC%extra, MRT, Css_min, Css_max, Css_av, DF, Css_min

    Time frame: 30 weeks

  9. The number of adverse events (AEs)/serious adverse events (SAEs) /AEs of special interest (AESIs) that occurred during the study.

    Time frame: 33 weeks

  10. Vital signs, physical examination, 12-lead Electrocardiogram (ECG), and clinical laboratory tests (hematology, urinalysis, blood biochemistry, blood amylase, blood lipase, coagulation function, calcitonin,TSH/FT3/FT4

    Change from baseline

    Time frame: 33 weeks

  11. Subject's mental health status (assessed by using the Columbia-Suicide Severity Rating Scale and Patient Health Questionnaire (PHQ-9))

    Time frame: 33 weeks

07

Study locations

1 site
  • Gan & Lee Pharmaceuticals Co., Ltd
    Beijing, China
08

References and documents

Publications

  • Ji L, Gao L, Tian J, Dong R, Zhang Z, Shu H, Zhao J, Zhao L, He A, Xie T, Li Y, Chen W. Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Signal Transduct Target Ther. 2026 Feb 27;11(1):73. doi: 10.1038/s41392-026-02586-8. PubMed 41760612 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jun 2024, 11 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 13, 2024
StartActual
Jun 8, 2023
Primary completionActual
Jun 5, 2024
CompletionActual
Jun 5, 2024
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06256562
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Jun 8, 2023
Primary completion
Jun 5, 2024
Completion
Jun 5, 2024
Last update
Oct 1, 2025

Study contacts

Liyuan Zhao, Ph.D
study director · Gan & Lee Pharmaceuticals.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion